Conatus announces top-line results from ENCORE-NF phase 2b clinical trial in NASH fibrosis
Conatus Pharmaceuticals announced top-line results from the company’s Phase 2b ENCORE-NF clinical trial in patients with biopsy-confirmed nonalcoholic steatohepatitis and liver fibrosis. The trial’s primary endpoint was a ≥1 CRN fibrosis stage improvement with no worsening of steatohepatitis. March 21, 2019